-
<![CDATA[How Modern Research Is Transforming Metastatic HER2+ Breast Cancer Care]]>
20 Dec 2025 01:16 GMT
… HER2-positive metastatic breast cancer are living longer …
Tyrosine kinase inhibitors: Tykerb (lapatinib), Nerlynx ( … of breast cancers, including aggressive triple-negative breast cancers, … breast cancer are cured? Typically, we treat metastatic breast cancer …
-
<![CDATA[Tucatinib Shows Improvement in PFS in Patients with HER2+ Metastatic Breast Cancer ]]>
16 Oct 2025 07:10 GMT
… 2-positive (HER2+) metastatic breast cancer (mBC).
The trial, HER2CLIMB … ) including pyrotinib (Irene), lapatinib (Tykerb), tucatinib, neratinib (Nerlynx), and afatinib … and Pertuzumab for Metastatic HER2+ Breast Cancer (HER2CLIMB-05). ClinicalTrials.gov. …
-
What You Need to Know About Breast Cancer Chemotherapy Pills
01 Jul 2025 14:46 GMT
… receptor 2 (HER2) positive breast cancer. These medications are typically administered … .
Other drugs, like lapatinib (Tykerb) and tucatinib (Tukysa), both … treatment of advanced HER2-positive breast cancer.
Capecitabine (Xeloda) and cyclophosphamide …
-
Breast Cancer and the Use of Predictive Genomics
18 Jun 2025 16:10 GMT
…
Predictive Genomics in Breast Cancers
Predictive genomics in breast cancer falls into 2 … lapatinib (Tykerb). Determination of the HER2 status of breast cancer is the … J. Breast cancer cell line classification and its relevance with breast tumor subtyping. …
-
Zanidatamab Plus Chemotherapy Shows Promising Anti-Tumor Activity in Treatment of HER2-Mutated Breast Cancer
21 May 2025 23:08 GMT
… (HER2)-mutated metastatic breast cancer (mBC). The data … for Medical Oncology Breast Cancer 2025 Annual Meeting … Genentech, Roche), lapatinib (24%; Tykerb; Novartis), trastuzumab deruxtecan (9% … HER2-mutated metastatic breast cancer, particularly those who …
-
Durvalumab Plus Tremelimumab and Trastuzumab Yields Clinical Activity in Trastuzumab-Resistant HER2+ Breast Cancer
16 May 2025 22:44 GMT
… resistant advanced HER2-postive breast cancer,” lead study author … , incurable HER2-positive breast cancer, irrespective of PD- … 4%; 17%) and lapatinib (Tykerb; 20%; 12%; 6%). Most … breast cancer: BCT1703 DIAmOND. Presented at: 2025 ESMO Breast Cancer Congress …
-
Zanidatamab/Chemotherapy Yields Responses and Is Safe in HER2-Expressing Metastatic Breast Cancer
16 May 2025 22:44 GMT
… patients with HER2-positive metastatic breast cancer who had previously received HER2 … advanced or metastatic HER2-expressing breast cancer with an ECOG performance status … ; 73%), pertuzumab (87%; 67%), lapatinib (Tykerb; 23%; 27%), tucatinib (6%; 13% …
-
New ADCs Aim to Strengthen the HER2+ Breast Cancer Paradigm and Join T-DXd and T-DM1
06 May 2025 14:44 GMT
… with HER2-positive metastatic breast cancer and again when it … survival (PFS) vs lapatinib (Tykerb) plus capecitabine and showed … Congress on the Future of Breast Cancer® (IBC) occurring on … ;West...[for] HER2-positive breast cancer in the curative setting, …
-
Neratinib Generates CNS Responses Across HER2+ Breast Cancer Brain Metastases Subgroups
10 Mar 2025 21:27 GMT
… treatments specifically targeting HER2-positive breast cancer brain metastases,” the authors explained … patients with no prior lapatinib (Tykerb) exposure, and cohort 3B ( … sequencing treatments for patients with breast cancer brain metastases,” the authors …
-
Systemic Therapies Are Now Preferred in Some Patients With HER2+ Breast Cancer Brain Metastases
08 Mar 2025 19:13 GMT
… T-DM1, lapatinib (Tykerb) plus capecitabine, and … with HER2-positive metastatic breast cancer for brain metastases … HER2+ Breast Cancer. Presented at: 42nd Annual Miami Breast Cancer Conference. … HER2-positive metastatic breast cancer and brain metastases: …